BOUNDLESS BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
BOUNDLESS BIO, INC. (BOLD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.20% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-07
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-06-30 was 4.20%, a 5.00% increase year-over-year.
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.90%, a 13.33% decline year-over-year.
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-09-30 was 4.20%, a 10.53% increase year-over-year.
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-06-30 was 4.00%, a 6.98% decline year-over-year.
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.40%, a 12.82% increase from fiscal 2024.
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.90%, a 0.00% change from fiscal 2023.
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.90%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.20% 10-Q · filed 2026-08-07 | 4.00% 10-Q · filed 2026-08-07 | ||
| 2026-03-31 | 3.90% 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | 4.40% 10-K · filed 2026-03-09 | |||
| 2025-09-30 | 4.20% 10-Q · filed 2025-11-05 | 4.40% 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | 4.00% 10-Q · filed 2026-08-07 | 4.40% 10-Q · filed 2026-08-07 | ||
| 2025-03-31 | 4.50% 10-Q · filed 2026-05-08 | |||
| 2024-12-31 | 3.90% 10-K · filed 2026-03-09 | |||
| 2024-09-30 | 3.80% 10-Q · filed 2025-11-05 | 3.90% 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | 4.30% 10-Q · filed 2025-08-05 | 4.20% 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | 4.20% 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | 3.90% 10-K · filed 2025-03-27 | |||
| 2023-09-30 | 3.90% 10-Q · filed 2024-11-07 | 3.90% 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | 3.90% 10-Q · filed 2024-08-12 | 3.90% 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | 3.60% 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |